Roche Holding's new gene-sequencing platform gives it a chance to take Illumina's crown in the market, Bernstein analysts say in a research note. The market for next-generation sequencing is expected to grow at an annual rate of 11% over the next decade to reach about $15.5 billion in 2035, and Roche can grab a 40% share, according to Bernstein. The diagnostics division of the Swiss pharma group is launching Axelios 1, a new sequencing product that has a cost and speed advantage over Illumina's rival product NovaSeq X Plus, the analysts say. Illumina held a quasi-monopoly of the market, but has faced competition from new entrants like U.S. rivals Element Biosciences and Ultima Genomics and China's MGI Tech in recent years, they add. Roche shares trade 0.2% higher. ([email protected])
Dow Jones Newswires
Roche Can Take Illumina's Crown With New Gene-Sequencing Tool — Market Talk
- Sources
- Dow Jones Newswires
- Markets
- Stocks
- Active symbols
- SIX:RO
- Language
- English
Roche Holding's new gene-sequencing platform gives it a chance to take Illumina's crown in the market, Bernstein analysts say in a research note. The market for next-generation sequencing is expected to grow at an annual rate of 11% over the next decade to reach about $15.5 billion in 2035, and Roc…